Analog device and test equipment

Abstract

The application discloses a simulation device and test equipment, the simulation device comprises: a human face model comprising human facial features; an airway piece; an absorber; an air source in communication with the absorber; wherein one end of the airway piece is in communication with the nostril of the human face model, and the other end is in communication with the absorber. Through the above arrangement, the airway piece is in communication with the nostril of the human face model, and the airway piece, the absorber and the air source are sequentially communicated. During the atomization process of the atomizer, the above simulation device can be used to simulate the human facial features and the real breathing state of the human body. The whole process of the aerosol generated by the atomizer being deposited on the face and inhaled through the nasal cavity can be completely simulated. The deposition amount of the aerosol on the human face model, the airway piece and the absorber of the simulation device and other parts can be counted, so that the facial deposition efficiency and the inhalation risk can be evaluated, and the problem that the facial deposition efficiency and the inhalation risk of the atomization product in the related art are difficult to evaluate is solved.

Description

Technical Field

[0001] This application relates to the field of atomization technology, and in particular to a simulation device and testing equipment. Background Technology

[0002] Currently, facial spray / mist products (such as hydrating, sun protection, makeup setting, and repair products) are becoming increasingly popular and have significant market potential. Spray droplets exert their effects through deposition and absorption; therefore, deposition amount is a crucial parameter for evaluating the performance of spray products. Deposition amount is influenced by parameters such as particle size distribution, atomization rate, and spray speed, but currently, there is no standardized measurement method for deposition amount.

[0003] Meanwhile, due to the small particle size of the aerosols generated by atomization, nebulized products pose a risk of inhalation through the nasal cavity and subsequent entry into the lungs. Unlike inhaled medications that aim to maximize lung dosage, facial sprays require a balance between high facial deposition efficiency and low inhalation risk.

[0004] However, in related technologies, it is difficult to assess the facial deposition efficiency and inhalation risk. Utility Model Content

[0005] This application mainly provides a simulation device and testing equipment to solve the problem that atomized products in related technologies are difficult to achieve facial deposition efficiency and inhalation risk assessment.

[0006] To solve the above-mentioned technical problems, one technical solution adopted in this application is: to provide a simulation device, comprising:

[0007] Human facial model, including human facial features;

[0008] Airway components;

[0009] Absorber;

[0010] The gas source is connected to the absorber;

[0011] One end of the airway is connected to the nostril of the human facial model, and the other end is connected to the absorber.

[0012] In some embodiments, the airway is a flexible tube, one end of which is inserted into the nostril of the human facial model, and the other end is connected to the absorber; or,

[0013] The airway component is a respiratory tract model, which includes a nasal cavity model, a larynx model, and a main trachea model connected in sequence; the entrance of the nasal cavity model is embedded in the nostril of the human face model, and the outlet of the main trachea model is connected to the absorber.

[0014] In some embodiments, the airway component is a respiratory tract model, and at least one of the nasal cavity model, the larynx model, and the main trachea model of the respiratory tract model is detachably connected.

[0015] In some embodiments, the airway component is a respiratory tract model, and the respiratory tract model is a transparent resin model.

[0016] In some embodiments, the inlet of the airway is bonded to the nostrils of the human facial model using adhesive material.

[0017] In some embodiments, the absorber is a high-efficiency particulate air filter.

[0018] In some embodiments, the gas source is a diaphragm pump or a piston pump.

[0019] In some embodiments, the human face model is an adult facial contour thin-shell model, the width of the human face model is 13-15cm, and the height of the human face model is 18-19cm.

[0020] To solve the above-mentioned technical problems, another technical solution adopted in this application is: to provide a testing device, comprising:

[0021] The simulation device as described above;

[0022] Atomizers are used to atomize aerosol generating matrix to generate aerosols.

[0023] The control circuit is electrically connected to both the simulation device and the atomizer, and is used to control the operation of the atomizer and the simulation device;

[0024] The aerosol generated by the atomizer is used to spray the human face model of the simulation device.

[0025] In some embodiments, the testing equipment further includes:

[0026] A measuring device is used to measure the mass of the atomizer before and after atomization, and to measure the mass of the human face model, the airway component, and the absorber before and after atomization.

[0027] The calculation circuit is used to obtain the mass of the atomizer before and after atomization, and the mass of the human face model, the airway component, and the absorber before and after atomization; calculate the mass reduction of the atomizer and the mass increase of the human face model, the airway component, and the absorber; and calculate the deposition ratio of the aerosol on the human face model, the airway component, and the absorber; and is used to calculate the deposition amount of the aerosol on the human face model, the airway component, and the absorber per unit time based on the atomization time of the atomizer.

[0028] In some embodiments, the computing circuit is further configured to compare the deposition ratio of the aerosol in the absorber with a first preset threshold; if the deposition ratio of the aerosol in the absorber is less than or equal to the first preset threshold, it is determined to be a low inhalation risk; and / or,

[0029] The computing circuit is also used to compare the deposition ratio of the aerosol on the human face model with a second preset threshold; if the deposition ratio of the aerosol on the human face model is greater than the second preset threshold, it is determined to be a high facial deposition efficiency.

[0030] In some embodiments, the air source is a diaphragm pump, which is used to simulate the inhalation process; the control circuit is used to control the diaphragm pump to complete the inhalation action at a frequency of 12-20 times per minute, and to control the diaphragm pump to pause for a preset time after each inhalation action before starting the next inhalation action; the control circuit is also used to control the flow rate of the diaphragm pump to be 14-16 L / min; or,

[0031] The air source is a piston pump, which is used to simulate the breathing process. The control circuit is used to control the piston pump to complete the cycle of the movement at a frequency of 12-20 times per minute. The piston pump alternately performs the pumping action and the exhaust action. One pumping action and one exhaust action of the piston pump constitute one movement cycle. The control circuit is also used to control the flow rate of the piston pump to be 29-31 L / min.

[0032] In some embodiments, the simulation device further includes a partition device disposed at the bottom of the human face model for isolating the spray field of the aerosol ejected by the atomizer from the air passage and the absorber.

[0033] In some embodiments, the aerosol-generating matrix of the atomizer includes a fluorescent colorimetric agent.

[0034] The beneficial effects of this application are as follows: Unlike existing technologies, this application discloses a simulation device and testing equipment. The simulation device includes: a human facial model, including facial features; an airway component; an absorber; and an air source connected to the absorber. One end of the airway component is connected to the nostrils of the human facial model, and the other end is connected to the absorber. Through this setup, the airway component is connected to the nostrils of the human facial model, and the airway component, absorber, and air source are sequentially connected in fluid. During the atomization process of the nebulizer, the simulation device can be used to simulate human facial features and the actual breathing state of a human. This allows for a complete simulation and reproduction of the entire process of aerosol deposition on the face and inhalation through the nasal cavity, facilitating the assessment of facial deposition efficiency and inhalation risk by statistically analyzing the aerosol deposition amounts on the human facial model, airway component, and absorber. This solves the problem in related technologies where atomized products struggle to assess facial deposition efficiency and inhalation risk. Attached Figure Description

[0035] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort, wherein:

[0036] Figure 1 This is a schematic diagram of an embodiment of the simulation device provided in the first embodiment of this application;

[0037] Figure 2 This is a schematic diagram of another embodiment of the simulation device provided in the first embodiment of this application;

[0038] Figure 3 This is a schematic diagram of an embodiment of the test equipment provided in the second embodiment of this application.

[0039] Icon labels:

[0040] 600. Testing equipment; 500. Nebulizer; 400. Control circuit; 300. Measuring device; 200. Calculation circuit; 100. Simulation device; 1. Human face model; 2. Airway components; 3. Absorber; 4. Air source; 5. Isolation device. Detailed Implementation

[0041] The technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only a part of the embodiments of this application, and not all of the embodiments. Based on the embodiments of this application, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of this application.

[0042] The terms "first," "second," and "third" used in the embodiments of this application are for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Thus, a feature defined as "first," "second," or "third" may explicitly or implicitly include at least one of that feature. In the description of this application, "multiple" means at least two, such as two, three, etc., unless otherwise explicitly specified. Furthermore, the terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusion. For example, a process, method, system, product, or device that includes a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units not listed, or may optionally include other steps or units inherent to these processes, methods, products, or devices.

[0043] In this document, the term "embodiment" means that a particular feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of this application. The appearance of this phrase in various places throughout the specification does not necessarily refer to the same embodiment, nor is it a mutually exclusive, independent, or alternative embodiment. It will be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.

[0044] See Figure 1 and Figure 2 , Figure 1 This is a schematic diagram of an embodiment of the simulation device provided in the first embodiment of this application. Figure 2 This is a schematic diagram of another embodiment of the simulation device provided in the first embodiment of this application.

[0045] See Figure 1 and Figure 2 The first embodiment of this application provides a simulation device 100, which includes a human face model 1, an airway component 2, an absorber 3, and an air source 4. The human face model 1 includes human facial features, one end of the airway component 2 is connected to the nostrils of the human face model 1, and the other end is connected to the absorber 3. The air source 4 is connected to the absorber 3.

[0046] Specifically, the human face model 1 simulates the structure of a real human face, including features such as the forehead, eyes, nose, mouth, and cheeks. The airway component 2, serving as a channel connecting the nostrils and the absorber 3, simulates the upper respiratory tract, i.e., it simulates the gas transport path from the nasal cavity to the lungs. The absorber 3 and air source 4 simulate the human lungs; the air source 4 simulates the respiratory function of the lungs, and the absorber 3 simulates the lungs' function of capturing inhaled aerosols.

[0047] It is understood that by connecting the airway component 2 to the nostrils of the human face model 1, and sequentially connecting the airway component 2, the absorber 3, and the air source 4, the above-mentioned simulation device 100 can be used to simulate human facial features and the actual breathing state of the human body. It can completely simulate and reproduce the entire process of aerosol deposition on the face and inhalation through the nasal cavity. It is convenient to assess the facial deposition efficiency and inhalation risk by statistically analyzing the amount of aerosol deposited on the human face model 1, airway component 2, and absorber 3 of the above-mentioned simulation device 100, thus solving the problem that atomized products in related technologies are difficult to assess facial deposition efficiency and inhalation risk.

[0048] In some embodiments, the human face model 1 is a thin-shell model of an adult facial contour. Specifically, the width of the human face model 1 is 13-15cm, and the height of the human face model 1 is 18-19cm, which can simulate the features of a real adult face and achieve a three-dimensional representation of the facial contour through the thin-shell structure. Specifically, the human face model 1 can be manufactured using 3D printing technology, and the material can be resin or other similar materials.

[0049] The dimensions of the human face model 1 are based on statistical analysis of typical adult facial dimensions, ensuring consistency between aerosol deposition distribution during the experiment and actual usage scenarios. By setting the human face model 1 to these specific dimensions, the physical contact area and morphological characteristics during facial spraying can be accurately reproduced, making the deposition test results closer to real-world usage scenarios. The thin-shell structure design ensures the three-dimensionality of the facial contours and surface curvature characteristics, facilitating the natural deposition of spray droplets in different areas. This dimensional setting provides the device with higher spatial resolution when evaluating facial deposition efficiency, significantly improving the accuracy of spray product performance evaluation.

[0050] In some embodiments, the airway component 2 is a respiratory tract model, which includes a nasal cavity model, a larynx model, and a main trachea model connected in sequence. The entrance of the nasal cavity model is embedded in the nostril of the human face model 1, and the outlet of the main trachea model is connected to the absorber 3. By setting the airway component 2 to the structure of the above-mentioned respiratory tract model, it can be used to realistically simulate the upper respiratory tract characteristics of the human nasal cavity, larynx, and main trachea, making it easier to more accurately reproduce the real human respiratory tract structure and breathing process. This facilitates the accurate assessment of aerosol deposition in various parts of the human upper respiratory tract during simulation experiments.

[0051] In some implementations, the respiratory tract model can be a transparent resin model. Specifically, the nasal cavity model, larynx model, and main trachea model of the respiratory tract are all made of transparent resin. The respiratory tract model can also be a 3D-printed transparent resin model based on CT scans, formed using CT scan data. It is understood that setting the respiratory tract model as a transparent resin model allows for direct observation of the inhalation and deposition distribution of aerosols within the respiratory tract model during simulated nebulization experiments, improving the visualization of experimental data. Furthermore, constructing the respiratory tract model based on CT scan data makes the experimental results more closely resemble real-world application scenarios.

[0052] In some implementations, at least one of the nasal cavity model, laryngeal model, and main trachea model of the respiratory tract model is detachably connected. Specifically, the respiratory tract model comprises separate structures of the nasal cavity model, laryngeal model, and main trachea model, with each part connected in a detachable manner. For example, connections can be made using snaps, threads, or adhesives.

[0053] It is understandable that by making at least one of the nasal cavity model, laryngeal model, and main trachea model detachable, it is convenient to measure and evaluate the deposition results of different parts of the respiratory tract model separately after the experiment. This facilitates the separate evaluation of the deposition amount in different parts of the respiratory tract model. The segmented detachable design enables refined analysis of the deposition in each part of the upper respiratory tract, improves the accuracy of experimental data, and significantly enhances the accuracy of experimental results. At the same time, the detachable connection structure also facilitates the individual cleaning or replacement of each functional component of the respiratory tract model after the experiment.

[0054] In other embodiments, the airway component 2 can also be a flexible tube, with one end embedded in the nostril of the human face model 1 and the other end connected to the absorber 3. It is understood that the airway component 2 is used to simulate the gas transport path from the nasal cavity to the lungs in a human body. The flexible tube used in the airway component 2 can simply simulate the characteristics of the human upper respiratory tract, and the total amount of aerosol deposition in the upper respiratory tract can be assessed by measuring the amount of aerosol deposition within the tube. Moreover, the simple structure of the flexible tube simplifies the structural complexity of the airway component 2 and facilitates cleaning.

[0055] In some embodiments, the inlet of the airway component 2 is bonded to the nostrils of the human face model 1 using adhesive. For example, the end of the nasal cavity model of the respiratory tract model away from the main trachea model is inserted into the nostril of the human face model 1, and the inlet end of the nasal cavity model is connected to the nostril of the human face model 1 using adhesive. Specifically, the adhesive can not only meet the connection requirements between the inlet of the airway component 2 and the nostrils of the human face model 1, but also fill the gap between the inlet of the airway component 2 and the nostrils of the human face model 1, so that the inlet of the airway component 2 and the nostrils of the human face model 1 can be sealed together, thereby facilitating the simulation of the movement of aerosols in the human nostrils and nasal cavity, and improving the accuracy of the evaluation results.

[0056] In one specific embodiment, the inlet of the airway component 2 and the nostrils of the human face model 1 can be bonded together using Blu-Tack. Blu-Tack has mild adhesion, high flexibility, and facilitates adjustment of the connection position and stability. When it is necessary to perform deposition effect analysis on the airway component 2 and the human face model 1 independently, the Blu-Tack can also be easily removed, thereby achieving disassembly of the airway component 2 and the human face model 1 without damaging the structure of the nostrils of the airway component 2 and the human face model 1. Furthermore, the Blu-Tack can be reused after disassembly, making it more suitable for scenarios requiring frequent disassembly or temporary fixation. In other embodiments, other adhesive materials can also be used to connect the inlet of the airway component 2 and the nostrils of the human face model 1.

[0057] In some embodiments, the absorber 3 can be a filter used to simulate the capture of aerosol particles inhaled into the lungs. Specifically, in some embodiments, the absorber 3 can be a Cambridge Analytic filter, or it can be a High Efficiency Particulate Air Filter (HEPA). Specifically, Cambridge Analytic filters or HEPA filters have significant advantages in particulate matter retention, achieving reliable interception of fine particles through high filtration efficiency. This makes experimental data closer to actual human inhalation conditions, ensuring accurate simulation of lung deposition during experiments, thereby improving the accuracy of lung deposition assessment results.

[0058] In some embodiments, the air source 4 can be a diaphragm pump or a piston pump. Using a diaphragm pump or piston pump as the power device to simulate lung breathing function, the diaphragm pump generates airflow through the reciprocating motion of the diaphragm, and the piston pump outputs airflow through the reciprocating motion of the piston, thereby simulating the human exhalation and inhalation process. Using a diaphragm pump or piston pump as the air source 4 can accurately simulate the airflow environment under different breathing conditions, making deposition and inhalation assessments more closely resemble actual usage scenarios. Specifically, during simulation experiments using the simulation device 100, the air source 4 can be controlled to move at the same frequency as the average adult respiratory rate, or controlled to move at the same flow rate as the average adult respiratory flow rate, so that the air source 4 can match the normal breathing conditions of adults, thereby more accurately reproducing actual usage scenarios, improving the accuracy of experimental data obtained from simulation experiments using the simulation device 100, and thus improving the accuracy of evaluation and analysis results.

[0059] See Figure 3 , Figure 3 This is a schematic diagram of an embodiment of the test equipment provided in the second embodiment of this application.

[0060] See Figure 3 The second embodiment of this application provides a test device 600, which includes a simulation device 100, an atomizer 500, and a control circuit 400.

[0061] The simulation device 100 can be any of the simulation devices 100 described above. The atomizer 500 is used to atomize the aerosol generating matrix to generate an aerosol. Specifically, the atomizer 500 can be any of the spray-type atomizers 500 used for facial atomization in the prior art. The aerosol generated by the atomizer 500 is sprayed onto the human face model 1 of the simulation device 100.

[0062] The control circuit 400 is electrically connected to both the simulation device 100 and the atomizer 500. The control circuit 400 is used to control the operation of the atomizer 500 and the simulation device 100 so that the test equipment 600 can be used to conduct simulation experiments to simulate the deposition of aerosols generated during the atomization process of the atomizer 500 in various parts of the simulation device 100. This allows the test equipment 600 to assess the facial deposition efficiency and inhalation risk, thus solving the problem that atomized products in related technologies are difficult to assess in terms of facial deposition efficiency and inhalation risk.

[0063] In some embodiments, the air source 4 of the simulation device 100 is a diaphragm pump, and the control circuit 400 is used to control the movement of the diaphragm pump. In one specific embodiment, the diaphragm pump can be used solely to simulate the unidirectional inhalation process of a normal adult, and the control circuit 400 is used to control the diaphragm pump to perform inhalation actions at a frequency of 12-20 times per minute to simulate the inhalation process. In some embodiments, the control circuit 400 can control the flow rate of the diaphragm pump to 14-16 L / min to match the inhalation frequency and flow rate of a normal adult, thereby simulating the inhalation state of a normal adult, facilitating accurate assessment of inhalation risk, and improving the accuracy of the assessment results.

[0064] In one specific embodiment, the control circuit 400 can control the diaphragm pump to pause for a preset time after each inhalation action. For example, the control circuit 400 controls the duration of each inhalation action of the diaphragm pump to be 2 seconds, and pauses for 2 seconds after each inhalation action, i.e., the preset time is 2 seconds, before proceeding to the next inhalation action, in order to better match the inhalation state of a normal adult. In this embodiment, the duration of each inhalation action is the same as the pause time, in order to better match the breathing state of an adult. In other embodiments, the pause time can also be slightly longer than the duration of the inhalation action. For example, the duration of the inhalation action can be 1 second, and the pause time can be 3 seconds, which can be designed according to needs.

[0065] In other embodiments, the diaphragm pump can also alternate between inhalation and exhalation, changing the pump chamber volume through the reciprocating motion of the diaphragm to achieve gas inhalation and exhalation, thereby simulating the inhalation and exhalation process of a normal adult and matching the complete breathing process. For example, the control circuit 400 can control the diaphragm pump to perform inhalation at a frequency of 12-20 times per minute and to perform exhalation at a frequency of 12-20 times per minute. In one specific embodiment, the control circuit 400 controls the duration of each inhalation and exhalation action of the diaphragm pump to be 2 seconds, and the duration of each exhalation action is also 2 seconds, controlling the diaphragm pump to alternate between inhalation and exhalation actions to better match the respiratory rate and respiratory flow of a normal adult, facilitating accurate assessment of inhalation risk and improving the accuracy of assessment results.

[0066] In some embodiments, the air source 4 of the simulation device 100 is a piston pump, which can perform reciprocating motions of suction and exhaust. The piston pump alternates between suction and exhaust actions. Specifically, one suction action and one exhaust action constitute one cycle to simulate a complete breathing process of a normal adult. For example, the control circuit 400 controls the piston pump to complete the cycle at a frequency of 12-20 times per minute. That is, the control circuit 400 controls the piston pump to complete 12-20 suction actions and 12-20 exhaust actions per minute to complete 12-20 cycles. In some embodiments, the control circuit 400 controls the flow rate of the piston pump to be 480-520 mL / s, or 29-31 L / min, to match the respiratory rate and flow rate of a normal adult's complete breathing process, thereby more accurately reproducing the breathing process of a normal adult, facilitating a more accurate assessment of inhalation risk, and improving the accuracy of the assessment results.

[0067] In some embodiments, the test apparatus 600 further includes a measuring device 300 and a computing circuit 200.

[0068] Specifically, in some embodiments, the measuring device 300 is used to measure the mass of the atomizer 500 before and after atomization, and to measure the mass of the human face model 1, the airway component 2, and the absorber 3 of the simulation device 100 before and after atomization, respectively. This allows for obtaining the mass reduction of the atomizer 500 after the atomization process, and the mass increase of the three different parts—the human face model 1, the airway component 2, and the absorber 3—after the atomization process. This facilitates the analysis of the deposition conditions at these three different parts. Specifically, the measuring device 300 can be any existing structural component used for measuring mass.

[0069] In other embodiments, the measuring device 300 can also be used to measure the mass of the atomizer 500 before and after atomization, and to measure the mass of the entire simulation device 100 before and after atomization. It can also measure the mass of the human face model 1 of the simulation device 100 before and after atomization, as well as the mass of the airway component 2 before and after atomization, so as to calculate the mass reduction of the atomizer 500 after the atomization process, and the mass increase of the three different parts of the human face model 1, the airway component 2, and the absorber 3 after the atomization process. This facilitates the analysis of the deposition situation of the three different parts of the human face model 1, the airway component 2, and the absorber 3.

[0070] In some embodiments, the computing circuit 200 is used to obtain the mass of the atomizer 500 before and after atomization, the mass of the human face model 1 before and after atomization, the mass of the airway component 2 before and after atomization, and the mass of the absorber 3 before and after atomization. It is used to calculate the mass reduction of the atomizer 500 and the mass increase of the human face model 1, the mass increase of the airway component 2, and the mass increase of the absorber 3, respectively, and to calculate the deposition ratio of aerosol in the three different parts of the human face model 1, the airway component 2, and the absorber 3.

[0071] In other embodiments, the measuring device 300 can also directly measure the mass reduction of the atomizer 500 after the atomization process, as well as the mass increase of the three different parts of the human face model 1, the airway component 2, and the absorber 3 after the atomization process; the calculation circuit 200 can directly obtain the mass reduction of the atomizer 500 and the mass increase of the human face model 1, the airway component 2, and the absorber 3, and calculate the deposition ratio of aerosol in the three different parts of the human face model 1, the airway component 2, and the absorber 3.

[0072] Specifically, the deposition ratio of aerosol on the human face model 1 is the ratio of the increase in mass of the human face model 1 to the decrease in mass of the atomizer 500; the deposition ratio of aerosol on the airway component 2 is the ratio of the increase in mass of the airway component 2 to the decrease in mass of the atomizer 500; and the deposition ratio of aerosol on the absorber 3 is the ratio of the increase in mass of the absorber 3 to the decrease in mass of the atomizer 500. By calculating the change in mass of each structural component through the calculation circuit 200, and calculating the deposition ratio of aerosol in each part, it is convenient to assess the area deposition efficiency and inhalation risk, thus solving the problem that atomized products in related technologies are difficult to assess facial deposition efficiency and inhalation risk.

[0073] In some embodiments, the calculation circuit 200 is also used to calculate the amount of aerosol deposited per unit time at three different locations—the human face model 1, the airway component 2, and the absorber 3—based on the atomization time of the nebulizer 500, to obtain the deposition efficiency of aerosols at these three locations. Specifically, the deposition efficiency of aerosols at the human face model 1 is the ratio of the mass increase of aerosols at the human face model 1 to the atomization time; the deposition efficiency of aerosols at the airway component 2 is the ratio of the mass increase of aerosols at the airway component 2 to the atomization time; and the deposition efficiency of aerosols at the absorber 3 is the ratio of the mass increase of aerosols at the absorber 3 to the atomization time. By calculating the deposition efficiency of aerosols at these three different locations—the human face model 1, the airway component 2, and the absorber 3—using the calculation circuit 200, the assessment of facial deposition efficiency and inhalation risk can be achieved.

[0074] In some embodiments, the computing circuit 200 is also used to compare the deposition ratio of aerosols in the absorber 3 with a first preset threshold to determine the inhalation risk of the aerosols. Specifically, if the deposition ratio of aerosols in the absorber 3 is less than or equal to the first preset threshold, it is determined to be a low inhalation risk, and for example, a low inhalation risk signal can be output. The first preset threshold can be set based on experience, or it can be set according to different usage requirements or actual product safety standards.

[0075] In some embodiments, the computing circuit 200 is also used to compare the deposition ratio of aerosols on the human face model 1 with a second preset threshold to determine the facial deposition efficiency. Specifically, if the deposition ratio of aerosols on the human face model 1 is greater than the second preset threshold, it is determined to be a high facial deposition efficiency, and for example, a high facial deposition efficiency signal can be output. The second preset threshold can also be set based on experience, or it can be set according to different usage requirements.

[0076] It is understood that by setting a first preset threshold and / or a second preset threshold, the calculation circuit 200 can quickly identify inhalation risk or facial deposition efficiency through threshold determination, which facilitates improved testing efficiency and enhances the objectivity and accuracy of test results.

[0077] In some implementations, such as Figure 2 As shown, the simulation device 100 also includes a partition device 5, which is located at the bottom of the human face model 1. The partition device 5 isolates the spray field of the aerosol sprayed by the atomizer 500 of the testing device 600 from the airway component 2 and the absorber 3. This prevents the aerosol sprayed by the atomizer 500 from reaching the outer surface of the airway component 2 and the outer surface of the absorber 3 through the bottom of the human face model 1, thus affecting the accuracy of the measured mass increase of the airway component 2 and the absorber 3, and consequently affecting the accuracy of the calculated deposition ratio and deposition efficiency of the three parts: the human face model 1, the airway component 2, and the absorber 3. By including the partition device 5 in the simulation device 100, interference from the spray field on the experimental results is avoided, which helps improve the accuracy of the evaluation results of the testing device 600. In some embodiments, the partition device 5 can be a baffle or a closed box structure to isolate the spray area of ​​the atomizer 500 from the airway component 2 and the absorber 3.

[0078] In other embodiments, the partition device 5 may be configured with other structures, or the simulation device 100 may not include the partition device 5, which can be designed as needed.

[0079] In some embodiments, the aerosol generating matrix of the nebulizer 500 of the testing device 600 includes a fluorescent colorimetric agent. With this configuration, combined with the transparent resin model structure of the airway component 2, the deposition and distribution of aerosols within the human face model 1 and the airway component 2 can be easily and intuitively observed, facilitating the visualization of experimental results. In one specific embodiment, the fluorescent colorimetric agent can be rhodamine fluorescent colorimetric agent.

[0080] In other embodiments, the aerosol generating matrix of the atomizer 500 may not include fluorescent colorimetric agents. Instead, the deposition amount and deposition efficiency at each site are measured and calculated using the measuring device 300 and the calculation circuit 200 to assess facial deposition efficiency and inhalation risk. The specific design can be tailored to the specific needs.

[0081] The above description is merely an embodiment of this application and does not limit the patent scope of this application. Any equivalent structural or procedural transformations made using the content of this application's specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the patent protection scope of this application.

Claims

1. A simulation device, characterized in that, include: Human facial model, including human facial features; Airway components; Absorber; The gas source is connected to the absorber; One end of the airway is connected to the nostril of the human facial model, and the other end is connected to the absorber.

2. The simulation device according to claim 1, characterized in that, The airway component is a flexible tube, one end of which is inserted into the nostril of the human facial model, and the other end is connected to the absorber; or, The airway component is a respiratory tract model, which includes a nasal cavity model, a larynx model, and a main trachea model connected in sequence; the entrance of the nasal cavity model is embedded in the nostril of the human face model, and the outlet of the main trachea model is connected to the absorber.

3. The simulation device according to claim 2, characterized in that, The airway component is a respiratory tract model, and at least one of the nasal cavity model, the larynx model, and the main trachea model of the respiratory tract model is detachably connected.

4. The simulation device according to claim 2, characterized in that, The airway component is a respiratory tract model, and the respiratory tract model is a transparent resin model.

5. The simulation device according to claim 1, characterized in that, The inlet of the airway is bonded to the nostrils of the human face model using adhesive material.

6. The simulation device according to claim 1, characterized in that, The absorber is a high-efficiency particulate air filter.

7. The simulation device according to claim 1, characterized in that, The gas source is a diaphragm pump or a piston pump.

8. A testing device, characterized in that, include: The simulation apparatus as described in any one of claims 1-7; Atomizers are used to atomize aerosol generating matrix to generate aerosols. The control circuit is electrically connected to both the simulation device and the atomizer, and is used to control the operation of the atomizer and the simulation device; The aerosol generated by the atomizer is used to spray the human face model of the simulation device.

9. The testing equipment according to claim 8, characterized in that, The testing equipment also includes: A measuring device is used to measure the mass of the atomizer before and after atomization, and to measure the mass of the human face model, the airway component, and the absorber before and after atomization. The calculation circuit is used to obtain the mass of the atomizer before and after atomization, and the mass of the human face model, the airway component, and the absorber before and after atomization; calculate the mass reduction of the atomizer and the mass increase of the human face model, the airway component, and the absorber; and calculate the deposition ratio of the aerosol on the human face model, the airway component, and the absorber; and is used to calculate the deposition amount of the aerosol on the human face model, the airway component, and the absorber per unit time based on the atomization time of the atomizer.

10. The testing equipment according to claim 9, characterized in that, The calculation circuit is also used to compare the deposition ratio of the aerosol in the absorber with a first preset threshold; if the deposition ratio of the aerosol in the absorber is less than or equal to the first preset threshold, it is determined to be low inhalation risk. And / or, The computing circuit is also used to compare the deposition ratio of the aerosol on the human face model with a second preset threshold; if the deposition ratio of the aerosol on the human face model is greater than the second preset threshold, it is determined to be a high facial deposition efficiency.

11. The testing equipment according to claim 8, characterized in that, The air source is a diaphragm pump, which is used to simulate the inhalation process; the control circuit controls the diaphragm pump to complete the inhalation action at a frequency of 12-20 times per minute, and controls the diaphragm pump to pause for a preset time after each inhalation action before starting the next inhalation action; the control circuit also controls the flow rate of the diaphragm pump to be 14-16 L / min; or, The air source is a piston pump, which is used to simulate the breathing process. The control circuit is used to control the piston pump to complete the cycle of the movement at a frequency of 12-20 times per minute. The piston pump alternately performs the pumping action and the exhaust action. One pumping action and one exhaust action of the piston pump constitute one movement cycle. The control circuit is also used to control the flow rate of the piston pump to be 29-31 L / min.

12. The testing equipment according to claim 8, characterized in that, The simulation device also includes a partition device located at the bottom of the human face model, used to isolate the spray field of the aerosol ejected by the atomizer from the air passage and the absorber.

13. The testing equipment according to claim 8, characterized in that, The aerosol-generating matrix of the atomizer includes a fluorescent colorimetric agent.

Images